You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 28, 2025

CLINICAL TRIALS PROFILE FOR STAUROSPORINE


✉ Email this page to a colleague

« Back to Dashboard


Clinical Trials for Staurosporine

Trial IDTitleStatusSponsorPhaseSummary
NCT00001444 ↗ A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms Completed National Cancer Institute (NCI) Phase 1 This is a dosage escalation study to estimate the maximum tolerated dose of staurosporine analogue UCN-01. Groups of 3 to 6 patients receive a 72-hours intravenous continuous infusions of UCN-01 from day 1 to day 4 of each cycle the first cycle only, and over 36-hours on subsequent cycles. The side effects are allowed to disappear for up to 28 days. This cycle is repeated after evaluations and follow-ups, which are every 4 weeks, as long as the patient benefits.
NCT00003289 ↗ UCN-01 in Treating Patients With Advanced Cancer Completed National Cancer Institute (NCI) Phase 1 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of UCN-01 in treating patients with advanced cancer that has not responded to previous treatment.
NCT00003289 ↗ UCN-01 in Treating Patients With Advanced Cancer Completed Sidney Kimmel Comprehensive Cancer Center Phase 1 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of UCN-01 in treating patients with advanced cancer that has not responded to previous treatment.
NCT00003289 ↗ UCN-01 in Treating Patients With Advanced Cancer Completed Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Phase 1 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of UCN-01 in treating patients with advanced cancer that has not responded to previous treatment.
>Trial ID>Title>Status>Phase>Summary
Showing 1 to 4 of 4 entries

Clinical Trial Conditions for Staurosporine

Condition Name

955500123456789Unspecified Adult Solid Tumor, Protocol SpecificLeukemiaLymphomaUntreated Adult Acute Myeloid Leukemia[disabled in preview]
Condition Name
Intervention Trials
Unspecified Adult Solid Tumor, Protocol Specific 9
Leukemia 5
Lymphoma 5
Untreated Adult Acute Myeloid Leukemia 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

1310107002468101214LeukemiaLeukemia, Myeloid, AcuteLeukemia, MyeloidNeoplasms[disabled in preview]
Condition MeSH
Intervention Trials
Leukemia 13
Leukemia, Myeloid, Acute 10
Leukemia, Myeloid 10
Neoplasms 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Staurosporine

Trials by Country

+
Trials by Country
Location Trials
United States 72
Canada 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

+
Trials by US State
Location Trials
Maryland 9
California 6
Texas 4
Ohio 4
New York 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Staurosporine

Clinical Trial Phase

35.5%6.5%54.8%0024681012141618Phase 2/Phase 3Phase 2Phase 1/Phase 2[disabled in preview]
Clinical Trial Phase
Clinical Trial Phase Trials
Phase 2/Phase 3 1
Phase 2 11
Phase 1/Phase 2 2
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

71.4%21.4%002468101214161820CompletedTerminatedSuspended[disabled in preview]
Clinical Trial Status
Clinical Trial Phase Trials
Completed 20
Terminated 6
Suspended 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Staurosporine

Sponsor Name

trials051015202530National Cancer Institute (NCI)University Health Network, TorontoSidney Kimmel Comprehensive Cancer Center[disabled in preview]
Sponsor Name
Sponsor Trials
National Cancer Institute (NCI) 28
University Health Network, Toronto 3
Sidney Kimmel Comprehensive Cancer Center 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

50.9%43.6%5.5%0051015202530NIHOtherIndustry[disabled in preview]
Sponsor Type
Sponsor Trials
NIH 28
Other 24
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.